Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Chengjie Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3194-0380; OpenAlex author ID A5086470404. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-025-08135-5↗
  2. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05715-1↗
  3. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05939-1↗
  4. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Co-author DOI 10.1186/s13062-022-00347-5↗
  5. N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer. Last author DOI 10.1186/s13578-022-00844-0↗
  6. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Co-author DOI 10.3389/fonc.2022.962204↗
  7. MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5. Co-author DOI 10.1016/j.cbi.2018.05.017↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangeng Weng · 6 shared papers, 2022–2026 · strength 1.20
  2. Shihui Lai · 5 shared papers, 2022–2026 · strength 1.03
  3. Xiang Zhang · 5 shared papers, 2022–2023 · strength 0.88
  4. Zhenyun Guo · 4 shared papers, 2022–2026 · strength 0.87
  5. Yue Huang · 3 shared papers, 2022–2023 · strength 0.55
  6. Yan Wang · 3 shared papers, 2022–2023 · strength 0.52
  7. Liang Wang · 2 shared papers, 2022 · strength 0.33
  8. Yun Zhong · 1 shared paper, 2022 · strength 0.16
  9. Guandou Yuan · 1 shared paper, 2018 · strength 0.08
  10. Songqing He · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.